Option chain shows key data for Alzamend Neuro's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alzamend Neuro.

Alzamend Neuro (NASDAQ:ALZN) Stock, Option Chain

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

ALZN

Biotech

News

Health Care

Exclusives

Movers

General

Alzamend Neuro&#39;s AL001 study highlights safety and therapeutic potential for Alzheimer&#39;s and psychiatric conditions, reducing systemic side effects.

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer&#39;s Drug Potential

Market-Moving Exclusives

Alzamend Neuro completed a Phase 2A study on AL001, identifying a safe lithium dose for Alzheimer&#39;s patients. The company plans further trials comparing brain lithium levels in Alzheimer&#39;s and other conditions.

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer&#39;s

movers image

Pre-Market Outlook

Markets

Trading Ideas

ASNS

BTBT

CING

ELBM

FLNT

GOVX

GSUN

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MLGO

NCNA

PITA

RERE

SIDU

SOND

TANH

TTNP

VIPS

Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Alzamend Neuro Inc

Oppenheimer analyst Michael Phillips initiates coverage on Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) with a Outperform rating and announces Price Target of $30.

Price Target

Initiation

Analyst Ratings

IGIC

Oppenheimer Initiates Coverage On Intl General Insurance with Outperform Rating, Announces Price Target of $30

SKK Shares Halted On Circuit Breaker To The Upside, Stock Now Up 123.5%

RBC Capital analyst Elvira Scotto reiterates EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) with a Sector Perform and maintains $15 price target.

Reiteration

ENLC

RBC Capital Reiterates Sector Perform on EnLink Midstream, Maintains $15 Price Target

JP Morgan analyst Christopher Horvers maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $167 to $139.

JP Morgan Maintains Neutral on Target, Lowers Price Target to $139

SKK Shares Resume Trade Following Circuit Breaker Halt

<ul>
<li>"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulation</li>
<li>New name is in advance of multiple near-term data readouts</li>
</ul>
&nbsp;
Therapeutic Program Update:
<ul>
<li>Depot Program for Postoperative Nerve Blocks – the Company showed a sustained release of drug over a 96-hour period in animals and is currently performing efficacy studies in animals, with results expected imminently. &nbsp;</li>
<li>Eye Pain Program – the eye drops were well tolerated in an animal study and the Company is performing efficacy studies in animal models of eye pain with toxicology studies starting shortly. The results of the efficacy studies are expected in the coming weeks and the toxicology data is expected in late Q1 2025. The Company expects to commence Phase II human proof of concept studies in Q2 2025, with a readout by the end of 2025. &nbsp;</li>
<li>Chronic Pain – the Company is exploring program-specific financing for this program with expectations that the program will be kicked off in Q1 2025.</li>
</ul>

CHRO

Chromocell Announces Name Change To "Channel Therapeutics Corporation"; Provides Therapeutic Program Updates

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $105 to $102.

RARE

JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $102

Polymarket bettors are speculating on Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) performance this November, with sharp focus on whether the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42096519/bitcoin-to-reach-190000-this-cycle-michael-terpin-of-transform-group-says">cryptocurrency will surpass $100,000.</a>
Current predictions on the platform <a href="https://polymarket.com/event/will-bitcoin-hit-100k-in-november">show</a> a 79% chance that Bitcoin will breach this milestone, fueled by the asset's recent all-time high of $98,310 and growing optimism in the market.
<h3 class="wp-block-heading">Bettors Lean Toward $105,000, Cautious Beyond</h3>
Beyond the $100,000 mark, Polymarket data <a href="https://polymarket.com/event/what-price-will-bitcoin-hit-in-november">indicates</a> a 46% probability for Bitcoin to hit $105,000 in November, while a rise to $110,000 is pegged at 25%.
However, optimism dims for more ambitious targets—only 9% of bettors see Bitcoin reaching $120,000, and just 1% believe it could hit $150,000 this month.
The cautious sentiment for extreme price hikes highlights the market's view of Bitcoin's upward limits this month, even as the cryptocurrency has shown consistent growth.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">Bitcoin Hits New All-Time High Above $98,000 As Spot ETFs Crack $100 Billion Net Asset Value Milestone</a>
<h3 class="wp-block-heading">Institutional Activity And ETF Inflows Boost Optimism</h3>
Bitcoin's rally is being bolstered by significant institutional activity. 
For example, MicroStrategy&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) plans to raise $2.6 billion to purchase more Bitcoin has pushed its market cap past $100 billion. 
Additionally, U.S. Bitcoin spot ETFs recorded $1.84 billion in net inflows over the past three days, showcasing rising demand <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">for Bitcoin as an asset class.</a>
These developments, combined with easing global monetary policies, are likely contributing to the bullish outlook for Bitcoin's price trajectory.
Bitcoin isn't the only cryptocurrency drawing attention. Polymarket bettors are also speculating on Ethereum and Solana's November performance. 
For Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), there's a 23% <a href="https://polymarket.com/event/what-price-will-ethereum-hit-in-november">chance </a>of hitting $4,000 in Novem, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) bettors assign a 47% <a href="https://polymarket.com/event/what-price-will-solana-hit-in-november?tid=1732196501984">probability </a>to the token crossing $275.
These markets indicate an overall bullish sentiment across major cryptocurrencies.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42071904/blackrock-sees-renewed-sense-of-optimism-around-bitcoin">BlackRock Sees &#8216;Renewed Sense Of Optimism&#8217; Around Bitcoin</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

MSTR

Bitcoin Price Hitting $100,000 In November? Polymarket Traders Speculate It Might Go Even Higher

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.74%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and boosted the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Nov. 20, Pfizer announced new Chief Scientific Officer and President, Research &amp; Development.</li>
<li>Benzinga Pro's real-time newsfeed alerted to la<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">test PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218.png" alt="" class="wp-image-658993" style="width:747px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218-768x703.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 5.18%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 78%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Nov. 13, Patterson Dental extended strategic relationship with PDS Health.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PDCO news </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="883" height="655" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219.png" alt="" class="wp-image-658996" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219-300x223.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219-768x570.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.68%</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 67%.</li>
<li>UBS analyst Kevin Celiendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Nov. 18, CVS Health announced the addition of four new directors to its board.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">in CVS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="847" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220.png" alt="" class="wp-image-658999" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220.png 847w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-300x300.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-768x771.png 768w" sizes="(max-width: 847px) 100vw, 847px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42103475/nvidia-deere-and-3-stocks-to-watch-heading-into-thursday">Nvidia, Deere And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

PDCO

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields

<a href="https://x.com/CitronResearch/status/1859608654590202325" title="https://x.com/CitronResearch/status/1859608654590202325">https://x.com/CitronResearch/status/1859608654590202325</a>

Short Sellers

Citron Research Posts On X ".. with Bitcoin investing easier than ever (ETFs, $COIN, $HOOD), $MSTR's volume has completely detached from BTC fundamentals. While Citron remains bullish on Bitcoin, we've hedged with a short $MSTR position.."

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $33 to $38.

SNDX

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $38

Financial giants have made a conspicuous bearish move on NVIDIA. Our analysis of options history for NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) revealed 509 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 42% showed bearish tendencies. Out of all the trades we spotted, 87 were puts, with a value of $5,771,224, and 422 were calls, valued at $42,566,316.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $0.5 to $280.0 for NVIDIA over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for NVIDIA options trades today is 29645.59 with a total volume of 6,724,021.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for NVIDIA's big money trades within a strike price range of $0.5 to $280.0 over the last 30 days.
<h3>NVIDIA Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732200460_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$33.95</td>
<td>$33.75</td>
<td>$33.84</td>
<td>$150.00</td>
<td>$795.2K</td>
<td>26.7K</td>
<td>543</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.9</td>
<td>$2.87</td>
<td>$2.9</td>
<td>$150.00</td>
<td>$219.9K</td>
<td>57.1K</td>
<td>24.2K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.85</td>
<td>$7.6</td>
<td>$7.73</td>
<td>$280.00</td>
<td>$181.7K</td>
<td>18.2K</td>
<td>539</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$150.00</td>
<td>$158.2K</td>
<td>57.1K</td>
<td>27.9K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.83</td>
<td>$2.8</td>
<td>$2.81</td>
<td>$150.00</td>
<td>$132.6K</td>
<td>57.1K</td>
<td>21.3K</td>
</tr>
</tbody>
</table>

<h3>About NVIDIA</h3>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
In light of the recent options history for NVIDIA, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is NVIDIA Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 48,977,431, the NVDA's price is up by 4.01%, now at $151.74. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On NVIDIA</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $177.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for NVIDIA, targeting a price of $175. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on NVIDIA, maintaining a target price of $170. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on NVIDIA, maintaining a target price of $167. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for NVIDIA, targeting a price of $190. 
&#x2A; Maintaining their stance, an analyst from Melius Research continues to hold a Buy rating for NVIDIA, targeting a price of $185. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for NVIDIA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

NVDA

Decoding NVIDIA's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HOOD, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 17 options trades for Robinhood Markets.
This isn't normal.
The overall sentiment of these big-money traders is split between 29% bullish and 64%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,800, and 16, calls, for a total amount of $1,056,398.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $40.0 for Robinhood Markets, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Robinhood Markets's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Robinhood Markets's whale activity within a strike price range from $30.0 to $40.0 in the last 30 days. 
<h3>Robinhood Markets Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732200454_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.31</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$39.00</td>
<td>$220.0K</td>
<td>2.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.65</td>
<td>$37.00</td>
<td>$146.0K</td>
<td>22.6K</td>
<td align="right">928</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.15</td>
<td>$5.05</td>
<td>$5.1</td>
<td>$34.00</td>
<td>$127.5K</td>
<td>3.4K</td>
<td align="right">257</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.91</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$40.00</td>
<td>$84.7K</td>
<td>17.7K</td>
<td align="right">957</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$7.95</td>
<td>$7.5</td>
<td>$7.75</td>
<td>$30.00</td>
<td>$77.5K</td>
<td>14.8K</td>
<td align="right">105</td>
</tr>
</tbody>
</table>

<h3>About Robinhood Markets</h3>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
Having examined the options trading patterns of Robinhood Markets, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Robinhood Markets</h3>
<ul>
<li>With a trading volume of 2,118,067, the price of HOOD is up by 2.25%, reaching $36.89.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Robinhood Markets</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $31.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Robinhood Markets with a target price of $26. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Robinhood Markets, maintaining a target price of $36. 
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Buy rating for Robinhood Markets, targeting a price of $32. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Robinhood Markets with a target price of $24. 
&#x2A; An analyst from Needham upgraded its action to Buy with a price target of $40. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Robinhood Markets, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

HOOD

Decoding Robinhood Markets's Options Activity: What's the Big Picture?

JP Morgan analyst Harlan Sur maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and raises the price target from $155 to $170.

JP Morgan Maintains Overweight on NVIDIA, Raises Price Target to $170

WORX

SCWorx Shares Halted On Circuit Breaker To The Upside, Stock Now Up 155.1%

<a href="https://www.benzinga.com/startups/24/11/42038731/jamie-dimon-warns-of-stagflation-looming-on-the-horizon-heres-the-financial-plan-experts-say-you-should-put-into-action-now">Jamie Dimon</a>, Chairman and CEO of JPMorgan Chase, has recently made headlines with his candid response to speculation about joining the federal government. While speaking at the APEC CEO Summit in Peru, Dimon addressed comments from <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways">President-elect Donald Trump</a>, who said that while he respected Dimon, Dimon would not be in the Treasury Secretary role in the incoming administration.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>
Dimon responded to the remarks, saying, "First of all, I wish the president well and thank you – that&#8217;s a very nice note. But I just want to tell the president also, I haven&#8217;t had a boss in 25 years. I&#8217;m not about ready to start."
Despite his disinterest in joining the Trump administration, Dimon offered insights into U.S. markets&#8217; direction and global economic policy. He acknowledged that the market response to Trump's election indicated a positive outlook, with investors hopeful about potential growth opportunities, including deregulation and tax reforms.&nbsp;
Dimon emphasized that the U.S. needs a long-term growth strategy to foster a stronger economy. "I think collaboration between government and business is the way to have growth," Dimon stated. He also supported a <a href="https://www.benzinga.com/startups/24/11/42041651/kevin-oleary-biden-harris-regulations-held-back-energy-but-markets-now-celebrate-expansion">deregulatory environment</a>, clarifying that this does not mean eliminating regulations entirely.&nbsp;
Trending: With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in the next few days</a>!
Instead, Dimon said that many regulations, particularly in countries like the U.S. and Peru (where he was speaking), have stifled growth. He suggested that inefficient regulatory environments are a major cause of this.&nbsp;
One area Dimon touched on in particular was the permitting process. He noted that inefficient government processes, including permit delays, can harm economic expansion. "I applaud any government that says I&#8217;m going to make government more efficient," Dimon remarked, stressing that improving the efficiency of government operations was essential for reducing frustrations that could fuel populism.
His leadership in the financial industry has defined Dimon's career. In 2000, he joined Bank One as its Chairman and CEO. When JPMorgan Chase merged with Bank One Corporation in 2004, Dimon was named President and COO of the newly merged organization. In 2006, Dimon became <a href="https://www.benzinga.com/startups/24/11/42024453/if-youre-in-a-knife-fight-you-better-damn-well-bring-a-knife-jpmorgan-ceo-jamie-dimon-calls-for-a-stand-against-regulation">CEO of JPMorgan Chase</a>, adding Chairman of the Board to his extensive resume only a year later.&nbsp;
See Also: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
Dimon's career spans decades, with earlier roles at American Express, Citigroup and Travelers group, where he was known for driving significant acquisitions and navigating complex corporate environments.
As one of the most influential figures in <a href="https://www.benzinga.com/startups/24/11/41885077/can-hong-kongs-ai-framework-lead-to-more-responsible-ai-use-in-global-finance">global finance</a>, Dimon's insights into the future of economic policy will likely continue to shape discussions on financial regulation, government efficiency and the path forward for American business. For now, however, Dimon seems content to focus on his role at JPMorgan, where he has thrived without needing a boss for over two decades.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai-2"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes in a few days.</a></li>
</ul>

'I Haven't Had A Boss For 25 Years, I'm Not About Ready To Start' – JPMorgan CEO Jamie Dimon Uninterested In Treasury Secretary Position

RBC Capital analyst Logan Reich maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Outperform and lowers the price target from $70 to $65.

JACK

RBC Capital Maintains Outperform on Jack In The Box, Lowers Price Target to $65

Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) launched the MAX OLED solution, a patented OLED pixel architecture and groundbreaking<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42109055/applied-materials-breakthrough-to-bring-oled-displays-to-tablets-pcs-and-tvs" rel="noreferrer noopener"> display manufacturing technology</a>.
This solution aims to bring the high-quality OLED displays found in premium smartphones to tablets, PCs, and eventually TVs.
OLED is the preferred display technology for top smartphone manufacturers due to its exceptional display quality, lightweight, flexible form factors, and durability.
However, scaling OLED display production for the larger glass panels used in tablets, PCs, and TVs has been a challenge—until now.
Applied&#8217;s MAX OLED solution simplifies the scaling of OLED manufacturing from Gen 6 to Gen 8 glass substrates, which are about twice as large, and beyond.
It also introduces a new method for depositing OLED materials, enhancing pixel brightness and resolution, reducing energy consumption, and extending the display&#8217;s lifespan.
The MAX OLED solution has generated strong customer interest, with repeat orders from several top display manufacturers.
Applied will also supply an alpha system to Samsung Display, a global leader in OLED and QD-OLED panels, for evaluation of this new technology.
Ross Young, Co-founder and CEO of Display Supply Chain Consultants (DSCC), said, &#8220;Applied Materials has developed a true breakthrough in OLED manufacturing technology that will enable better OLED displays at more attractive prices,&#8221;
&#8220;This technology has the potential to accelerate OLED adoption in a range of markets, from tablets and PCs to automobiles and micro-displays for AR/VR, creating a catalyst for the entire display industry.&#8221;
Investors can gain exposure to the stock via&nbsp;First Trust Nasdaq Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXL#NASDAQ">FTXL</a>) and Pacer BlueStar Engineering the Future ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULD#NASDAQ">BULD</a>).
Price Action: AMAT shares are up 0.90% at $172.03 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42105339/mohamed-el-erian-warns-against-simplistic-narratives-as-trump-plans-aggressive-tariff-strategy-the-issue-is-quite-complex" target="_blank" rel="noreferrer noopener">Mohamed El-Erian Warns Against Simplistic Narratives As Trump Plans Aggressive Tariff Strategy: &#8216;The Issue Is Quite Complex&#8217;</a></li>
</ul>

Equities

Large Cap

AMAT

BULD

FTXL

Breaking New Ground In OLED: Applied Materials Unveils MAX OLED Solution For Bigger Displays

Piper Sandler analyst Peter Keith maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $156 to $130.

Piper Sandler Maintains Neutral on Target, Lowers Price Target to $130

WIIM

Deere & Company shares are trading higher after they company announced better-than-expected Q4 financials.

Alzamend Neuro (ALZN) has provided an update. On July 12, 2024, the Company announced a Reverse Stock Split, highlighting that this move is not an ...

Alzamend Neuro Announces Reverse Stock Split Decision

Alzamend Neuro (ALZN) just unveiled an update. Alzamend Neuro, Inc. successfully regained compliance with Nasdaq's Minimum Bid Price Requirement af...

Alzamend Neuro Meets Nasdaq Standards, Embraces Social Media

Warning: ALZN is at high risk of performing badly

Alzamend Neuro regains compliance with Nasdaq

Alzamend Neuro ( ($ALZN) ) has issued an announcement. Alzamend Neuro, a biopharmaceutical company targeting Alzheimer's and other disorders, succe...

Alzamend Neuro Regains Nasdaq Compliance After Strategic Appeal

Press Releases

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro Issues Letter to Stockholders

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group's Virtual Healthcare Conference

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice

Comments

Alzamend Neuro

Alzamend Neuro (ALZN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga